Video

Segment 3 - Justifying Costs: A Request for More Evidence

Payers are often hesitant to cover more expensive, newly approved therapies. Many want to base their formulary decisions on evidence, which in many cases is limited. Richard Joseph, MD, describes this as “a difficult dilemma,” adding that “Trying to get an evidence for each scenario is a really challenging thing.”

Collecting evidence can be costly and may not provide more insight into justifying a therapy’s use, and cost, than a provider’s expert opinion. Still, care and coverage are often dictated by an individual’s form of insurance. Ideally, as data on new therapies and their costs accumulate, coverage and reimbursement considerations will align more and more closely with the evidence

Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs


Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
CH LogoCenter for Biosimilars Logo